Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZYMEWORKS INC (US)

12.57
+0.05000.40%
Post-market: 12.570.00000.00%19:40 EDT
Volume:370.38K
Turnover:4.62M
Market Cap:874.58M
PE:-7.77
High:12.58
Open:12.41
Low:12.23
Close:12.52
Loading ...

Zymeworks - Look Forward to Advancing ZW209 With Ind Submission Anticipated in H12026

THOMSON REUTERS
·
Yesterday

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

GlobeNewswire
·
Yesterday

Zymeworks Appoints DR. Sabeen Mekan as Senior Vice President, Clinical Development

THOMSON REUTERS
·
21 Apr

Press Release: Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Dow Jones
·
21 Apr

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

GlobeNewswire
·
17 Apr

Couchbase, Staar Surgical, Zymeworks, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
12 Apr

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

GlobeNewswire
·
26 Mar

Zymeworks (ZYME) Receives a Buy from LifeSci Capital

TIPRANKS
·
11 Mar

Top Premarket Decliners

MT Newswires Live
·
11 Mar

Zymeworks initiated with an Outperform at LifeSci Capital

TIPRANKS
·
11 Mar

Zymeworks Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
11 Mar

Zymeworks price target raised to $13 from $12 at H.C. Wainwright

TIPRANKS
·
10 Mar

Zymeworks, Inc. : H.c. Wainwright Raises Target Price to $13 From $12

THOMSON REUTERS
·
10 Mar

Zymeworks Is Maintained at Buy by Citigroup

Dow Jones
·
08 Mar

Zymeworks price target raised to $19 from $18 at Citi

TIPRANKS
·
07 Mar

Zymeworks Faces Challenges in Diagnostic Test Development Amidst Regulatory Changes

TIPRANKS
·
07 Mar

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Benzinga
·
07 Mar

Zymeworks Down Over 8%, on Pace for Largest Percent Decrease Since December 2022 -- Data Talk

Dow Jones
·
07 Mar

Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)

TIPRANKS
·
06 Mar

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Teva Pharmaceutical (TEVA) and Incyte (INCY)

TIPRANKS
·
06 Mar